
WHAT IS CLAIMED IS:

1. An amorphous form of Compound (I) of the formula



(I).

2. The amorphous form of claim 1 prepared by freeze drying, spray drying, evaporation, lyophilization, or any combination thereof.

3. The amorphous form of claim 2 characterized by PXRD as depicted in FIG. 1.

4. The amorphous form of claim 2 characterized by modulated DSC as depicted in FIG. 2.

5. The amorphous form of claim 2 characterized by PXRD as depicted in FIG. 3.

6. The amorphous form of claim 2 characterized by modulated DSC as depicted in FIG. 4.

7. The amorphous form of claim 2 characterized by solid-state NMR as depicted in FIG. 5.

8. A method for producing an amorphous solid dispersion of Compound (I), the method comprising:


(a) preparing a liquid solution comprising Compound (I), at least one polymer and a solvent; and

(b) spray drying the liquid solution, thereby producing the amorphous solid dispersion.

9. The method of claim 8, wherein the liquid solution comprises at least one solvent selected from the group consisting of: acetone, tetrahydrofuran, alcohol, ethyl acetate, methyl ether ketone, dichloromethane, and water.

10. The method of claim 8, wherein the polymer is selected from the group consisting of: PVP, PVP-vinyl acetate copolymer, HPMCAS, and HPMC.

11. An amorphous solid dispersion comprising Compound (I) of the formula



(I)

thereof and a polymer wherein the polymer is selected from the group consisting of PVP, HPMCAS and HPMC.

12. The dispersion of claim 11 wherein the polymer is HPMCAS.

13. The dispersion of claim 11 wherein the ratio of Compound (I) to polymer is in the range of from 99 to 75% (w/w) Compound (I) and from 1 to 25% (w/w) polymer.

14. The dispersion of claim 11 wherein the ratio of Compound (I) to polymer is in the range of from 74 to 50% (w/w) Compound (I) and from 26 to 50% (w/w) polymer.

15. The dispersion of claim 11 wherein the ratio of Compound (I) to polymer is in the range of from 49 to 25% (w/w) Compound (I) and from 51 to 75% (w/w) polymer.

16. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the dispersion of claim 11.

17. The pharmaceutical composition of claim 16, wherein the composition is in the form of a tablet.

18. The pharmaceutical composition of claim 16, wherein the composition is in the form of a capsule.

19. The pharmaceutical composition of claim 16, wherein the composition is in the form of a suspension.

20. The pharmaceutical composition of claim 17 or 18, wherein the tablet and capsule are storage stable for at least about 3 months.